Your browser doesn't support javascript.
loading
Determinants of stimulated salivary flow among haematopoietic stem cell transplantation recipients.
Mauramo, Matti; Rohde, Luzius; Ramseier, Adrian M; Rovó, Alicia; Waltimo, Tuomas.
Afiliação
  • Mauramo M; Institute of Preventive Dentistry and Oral Microbiology, School of Dental Medicine, University of Basel, Basel, Switzerland. matti.mauramo@helsinki.fi.
  • Rohde L; Institute of Dentistry, Scientific Research Laboratory, Biomedicum, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, FI-00014, Helsinki, Finland. matti.mauramo@helsinki.fi.
  • Ramseier AM; Institute of Preventive Dentistry and Oral Microbiology, School of Dental Medicine, University of Basel, Basel, Switzerland.
  • Rovó A; Institute of Preventive Dentistry and Oral Microbiology, School of Dental Medicine, University of Basel, Basel, Switzerland.
  • Waltimo T; Department of Haematology, University Hospital Basel, Basel, Switzerland.
Clin Oral Investig ; 21(1): 121-126, 2017 Jan.
Article em En | MEDLINE | ID: mdl-26911494
ABSTRACT

OBJECTIVES:

The aetiology of hyposalivation in haematopoietic stem cell transplantation (HSCT) recipients is not fully understood. This study examined the effects of treatment-related aetiological factors, particularly medications, on stimulated salivary flow in HSCT recipients. SUBJECTS AND

METHODS:

Adult HSCT recipients (N = 118, 66 males, 27 autologous and 91 allogeneic transplants) were examined. Stimulated whole salivary flow rates (SWSFR) were measured before HSCT and at 6 and 12 months post-HSCT. Linear regression models were used to analyse the associations of medications and transplant-related factors with salivary flow rates, which were compared to salivary flow rates of generally healthy controls (N = 247).

RESULTS:

The SWSFR of recipients were lower pre-HSCT (mean ± standard deviation, 0.88 ± 0.56 ml/min; P < 0.001), 6 months post-HSCT (0.84 ± 0.61; P < 0.001) and 12 months post-HSCT (1.08 ± 0.67; P = 0.005) than the SWSFR of controls (1.31 ± 0.65). In addition, hyposalivation (<0.7 ml/min) was more frequent among HSCT recipients pre-HSCT (P < 0.001), 6 months post-HSCT (P < 0.001) and 12 months post-HSCT (P = 0.01) than among controls. The SWSFR was observed to improve over time being significantly higher 12 months post-HSCT compared to pre-HSCT (P < 0.001). The observed decrease of salivary flow could not be explained by the examined transplant-related factors and medications.

CONCLUSIONS:

Decreased stimulated salivary flow rates could not be explained by the examined factors alone; these findings indicate that hyposalivation in HSCT recipients exhibits a multifactorial aetiology. CLINICAL RELEVANCE All HSCT recipients should be considered to be at high risk of hyposalivation and consequent oral diseases, and they should be treated accordingly.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Xerostomia / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Xerostomia / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2017 Tipo de documento: Article